Stem cell factor

1 - 70 . (canceled)

71 . A method of treating a hematopoietic disorder characterized by reduction in bone marrow mass, comprising the step of administering to a human an effective amount of a human stem cell factor (SCF) polypeptide and optionally a pharmaceutically acceptable carrier.

72 . The method of claim 71 wherein the stem cell factor (SCF) polypeptide is selected from the group consisting of amino acids 1-162, 1-164, and 1-165 as set out in-SEQ ID NO: 46, said polypeptide optionally consisting of an N-terminal methionine.

73 . The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in SEQ ID NO 61, said polypeptide optionally consisting of an N-terminal methionine.

74 . The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in SEQ ID NO 63, said polypeptide optionally consisting of an N-terminal methionine.

75 . The method of claim 71 wherein the stem cell factor is covalently conjugated to a water-soluble polymer.

76 . The method of claim 75 wherein the water-soluble polymer is polyethylene glycol.

77 . The method of claim 71 wherein the stem cell factor is SCF 1-164 PEG 25.

78 . The method of claim 71 wherein the stem cell factor is SCF 1-193 .

79 . The method of claim 71 wherein the stem cell factor is co-administered with at least one other cytokine and optionally a pharmaceutically acceptable carrier.

80 . The method of claim 79 wherein one or more cytokines are selected from a group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), Macrophage Colony Stimulating Factor (M-CSF) granulocyte-monocyte colony stimulating factor (GM-CSF), insulin growth factor-1 (IGF-1) and leukemia inhibitory factor (LIF).

81 . The method of claim 80 wherein the cytokine is granulocyte colony stimulating factor (G-CSF).

82 . The method of claim 75 wherein the stem cell factor is co-administered with at least one other cytokine.

83 . The method of claim 82 wherein the cytokine is selected from a group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), Macrophage Colony Stimulating Factor (M-CSF), granulocyte-monocyte colony stimulating factor (GM-CSF), insulin growth factor-1 (IGF-1), and leukemia inhibitory factor (LIF).

84 . The method of claim 83 wherein the cytokine is granulocyte colony stimulating factor (G-CSF).

85 . The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

86 . The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for pulmonary delivery.

87 . The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for nasal delivery.

88 . The method of claim 71 wherein the hematopoietic disorder is selected from the group consisting of aplastic anemia, Diamond-Blackfan anemia (DBA), Fanconi's anemia, dyskeratosis congenita, amegakaryocytic thrombocytopenia, thrombocytopenia with absent radii, congenital agranulocytosis (e.g. Kostmann's syndrome, Shwachman-Diamond syndrome), and idiopathic and cyclic neutropenia.

89 . The method of claim 71 wherein the hematopoietic disorder is aplastic anemia.